Take part in a paid clinical trial

Friedreich’s Ataxia (FA) is a rare, inherited disease that affects the nervous system, muscles, and heart. Symptoms often begin in childhood or adolescence and can progressively impact balance, coordination, walking, speech, and daily activities. Over time, many people with FA experience increasing disability, and serious complications such as heart disease can occur. 

FA is caused by a genetic change that reduces production of a protein called frataxin, which is essential for normal cell function. Because the underlying cause of FA is not fully addressed by current treatment options, there remains a significant need for new therapies that may help restore frataxin levels and potentially slow or modify disease progression. 

We invite you to join our Phase 1 clinical study evaluating an investigative treatment for FA. By participating, you can offer hope to affected families and contribute to a future where FA no longer limits lives. 

This clinical study is investigating a new oral medication for plaque psoriasis, a chronic autoimmune condition which can lead to raised patches of dry and itchy skin. The purpose of the study is to better understand the safety of the medication, how it is processed by the body, and how the body responds to it. By conducting this study, researchers hope to gain a better understanding of the medication and how it behaves in different populations, which may help support future clinical development and the design of larger studies in people with plaque psoriasis. 

This study is sponsored by a pharmaceutical company.

This clinical study is investigating an investigational vaccine targeting respiratory viruses such as RSV, HMPV and PIV. This investigational vaccine is being developed to address the lack of currently licensed vaccines for prevention of HPMV and PIV. Researchers are evaluating this investigational vaccine to better understand its safety, tolerability and how the body responds to it. 

By conducting this study, researchers hope to gain a better understanding of the medication and how it behaves in different populations, which may help support future clinical development and the design of subsequent research studies to help with protection from respiratory viruses. 

This study is sponsored by a pharmaceutical company.

This clinical study is investigating a new oral medication for plaque psoriasis, a chronic autoimmune condition which can lead to raised patches of dry and itchy skin. The purpose of the study is to better understand the safety of the medication, how it is processed by the body, and how the body responds to it. By conducting this study, researchers hope to gain a better understanding of the medication and how it behaves in different populations, which may help support future clinical development and the design of larger studies in people with plaque psoriasis. 

This study is sponsored by a pharmaceutical company.